Status:
TERMINATED
IGFD Registry: A Patient Registry for Monitoring Long-term Safety and Efficacy of Increlex
Lead Sponsor:
Ipsen
Conditions:
Primary Insulin-like Growth Factor-1 Deficiency
Eligibility:
All Genders
Brief Summary
This project is a retrospective (beginning January 2006) and prospective patient registry program sponsored by Ipsen (formerly Tercica, Inc.). In collaboration with participating health care practitio...
Detailed Description
The data collected for a patient will be those that exist in the patient's medical record as part of standard medical care. No additional patient procedures or activities are mandated by this study. T...
Eligibility Criteria
Inclusion
- Parents or legally authorized representatives must give signed informed consent before any Registry-related activities are conducted. Assent from the subject should also be obtained where appropriate.
- Patients receiving Increlex® by a qualified practitioner may be enrolled
Exclusion
Key Trial Info
Start Date :
June 1 2006
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
May 1 2014
Estimated Enrollment :
1378 Patients enrolled
Trial Details
Trial ID
NCT00747604
Start Date
June 1 2006
End Date
May 1 2014
Last Update
November 6 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Ipsen Central Contact
Basking Ridge, New Jersey, United States, 07920